ArticleJournal of clinical medicine2025

Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study.

Luciano Ibba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.